Low RPS14 expression is common in myelodysplastic syndromes without 5q- aberration and defines a subgroup of patients with prolonged survival

Haematologica

Volumn 94, Issue 10, 2009, Pages 1453-1455

  Czibere, Akos ^a   Bruns, Ingmar ^a   Junge, Bärbel ^a   Singh, Raminder ^a   Kobbe, Guido ^a   Haas, Rainer ^a   Germing, Ulrich ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

5q aberration; Low RPS14; Myelodysplastic syndromes; Prolonged survival

Indexed keywords

PROTEIN RPS 14; RIBOSOME PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE MARROW; CANCER SURVIVAL; CD34 SELECTION; CHROMOSOME 5Q; CHROMOSOME ABERRATION; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROME; PROGNOSIS; SCORING SYSTEM;

ADULT; AGED; AGED, 80 AND OVER; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 5; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; REGISTRIES; RIBOSOMAL PROTEINS; SURVIVAL RATE;

EID: 70349643737     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2009.008508     Document Type: Article

References (11)

1. Boultwood J, Lewis S, Wainscoat JS. The 5q-syndrome. Blood 1994;84: 3253-3260
2. Giagounidis AA, Germing U, Haase S, Hildebrandt B, Schlegelberger B, Schoch C, et al. Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31. Leukemia 2004;18:113-119 (Pubitemid 38159446)
3. Haase D, Germing U, Schanz J, Pfeilstocker M, Nosslinger T, Hildebrandt B, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 2007;110: 4385-4395
4. Ebert BL, Pretz J, Bosco J, Chang CY, Tamayo P, Galili N, et al. Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature 2008;451:335-339
5. Sohal DS, Pellagatti A, Zhou L, Mo Y, Opalinska JB, Alencar C, et al. Downregulation of ribosomal proteins is seen in non-5q- MDS. Blood 2008 (ASH Annual Meeting Abstracts);112[Abstract 854].
6. Bruns I, Steidl U, Fischer JC, Czibere A, Kobbe G, Raschke S, et al. Pegylated granulocyte colony-stimulating factor mobilizes CD34+ cells with different stem and progenitor subsets and distinct functional properties in comparison with unconjugated granulocyte colony-stimulating factor. Haematologica 2008;93: 347-355
7. Boultwood J, Pellagatti A, Cattan H, Lawrie CH, Giagounidis A, Malcovati L, et al. Gene expression profiling of CD34+ cells in patients with the 5q- syndrome. Br J Haematol 2007;139:578-589 (Pubitemid 350043812)
8. Valencia A, Cervera J, Such E, Sanz MA, Sanz GF. Lack of RPS14 promoter aberrant methylation supports the haploinsufficiency model for the 5q- syndrome. Blood 2008;112:918.
9. Boultwood J, Fidler C, Strickson AJ, Watkins F, Gama S, Kearney L, et al. Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome. Blood 2002;99: 4638-4641 (Pubitemid 34627240)
10. Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-2088 (Pubitemid 27132124)
11. Ebert BL, Galili N, Tamayo P, Bosco J, Mak R, Pretz J, et al. An erythroid differentiation signature predicts response to lenalidomide in myelodysplastic syndrome. PLoS Med 2008;5:e35. (Pubitemid 351317661)